Latest Annual Reports
by Mike Gee
20 November 2026









































ATOSSA THERAPEUTICS, INC.
REVENUE
N/A
INCOME
-$34,800,000
-36.45%
EMPLOYEES
N/A
CUSTOMERS
N/A
Clinical-stage biopharmaceutical company developing oral (Z)-endoxifen for breast cancer indications (risk reduction and neoadjuvant settings) and select rare pediatric diseases.
View Company PageFiled: 2026-03-25
DYADIC INTERNATIONAL INC
REVENUE
$3,090,345
-11.59%
INCOME
-$7,364,628
-26.78%
EMPLOYEES
5
CUSTOMERS
14
Dyadic Applied BioSolutions is a Jupiter, Florida–based biotechnology company that develops, manufactures, and commercializes animal-free recombinant proteins and enzymes for life sciences, food & nutrition, and bio-industrial markets using its proprietary C1 and Dapibus microbial expression platforms.
View Company PageFiled: 2026-03-25
ACHIEVE LIFE SCIENCES, INC.
REVENUE
N/A
INCOME
-$54,648,000
-37.21%
EMPLOYEES
28
CUSTOMERS
N/A
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company developing cytisinicline to treat nicotine dependence (primarily smoking and vaping cessation) with principal offices in Bothell, WA and Vancouver, BC.
View Company PageFiled: 2026-03-24
Audax Private Credit Fund, LLC
REVENUE
$64,857,029
INCOME
$28,070,675
EMPLOYEES
81
CUSTOMERS
16
The Fund is a newly formed, permanent, non-exchange-traded BDC that seeks current income and some capital appreciation by investing primarily in directly originated senior secured first‑lien loans to privately held U.S. middle‑market companies, with limited exposure to second‑lien and mezzanine debt, equity‑like instruments, and opportunistic liquid credits, managed through a structured relationship with Audax Private Debt and its affiliates.
View Company PageFiled: 2026-03-24
Andretti Acquisition Corp. II
REVENUE
N/A
INCOME
$8,350,365
EMPLOYEES
2
CUSTOMERS
N/A
Andretti Acquisition Corp is a Cayman Islands special purpose acquisition company formed May 21, 2024 to effect an initial business combination, raised $230.0M in an IPO plus $7.6M in a private placement, holds trust assets for a target transaction, and has no operating revenues to date.
View Company PageFiled: 2026-03-24
AB Commercial Real Estate Private Debt Fund, LLC
REVENUE
$78,999,000
4.44%
INCOME
$25,188,000
-12.37%
EMPLOYEES
N/A
CUSTOMERS
N/A
A private Delaware limited liability company formed in 2021 that operates as a REIT-focused investment fund targeting U.S. commercial real estate debt and related assets, managed by an SEC-registered investment manager.
View Company PageFiled: 2026-03-24
Absci Corp
REVENUE
$2,800,000
-38.24%
INCOME
-$115,183,000
-11.71%
EMPLOYEES
140
CUSTOMERS
3
Absci is a clinical-stage biopharmaceutical company that uses an AI-native Integrated Drug Creation platform to design and rapidly validate antibody therapeutics and advances internal programs while generating partner-derived revenue.
View Company PageFiled: 2026-03-24
Aardvark Therapeutics, Inc.
REVENUE
N/A
INCOME
-$57,591,000
-179.73%
EMPLOYEES
N/A
CUSTOMERS
N/A
Clinical-stage biopharmaceutical company developing oral small-molecule TAS2R agonists (lead ARD-101) to stimulate endogenous gut hormones and suppress hunger for metabolic diseases.
View Company PageFiled: 2026-03-23
Aterian, Inc.
REVENUE
N/A
INCOME
-$19,000,000
-60.18%
EMPLOYEES
74
CUSTOMERS
N/A
Consumer products company that owns and markets multiple consumer brands and primarily sells online through e-commerce marketplaces (predominantly Amazon US) and direct-to-consumer websites.
View Company PageFiled: 2026-03-23
Avalo Therapeutics, Inc.
REVENUE
$59,000
-86.62%
INCOME
-$78,300,000
-122.89%
EMPLOYEES
33
CUSTOMERS
N/A
Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), a high-affinity anti-IL-1β monoclonal antibody primarily for hidradenitis suppurativa, currently in a Phase 2 LOTUS trial with topline data expected in Q2 2026 and no approved products to date.
View Company PageFiled: 2026-03-23
Arbutus Biopharma Corp
REVENUE
$14,083,000
128.21%
INCOME
-$33,501,000
52.09%
EMPLOYEES
19
CUSTOMERS
N/A
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing curative therapies for chronic hepatitis B, advancing RNAi therapeutic AB-729 (imdusiran) and oral PD-L1 inhibitor AB-101 while monetizing LNP/IP through collaborations and licensing.
View Company PageFiled: 2026-03-23
AMBARELLA INC
REVENUE
$390,702,000
37.15%
INCOME
-$75,865,000
35.23%
EMPLOYEES
959
CUSTOMERS
N/A
Ambarella designs and sells low-power system-on-chip processors and software for edge and physical AI, enabling on-device multi-modal sensor fusion and inference for IoT, automotive, robotics, and edge computing applications.
View Company Page